Low-dose radon hyperthermia therapy in atopic dermatitis

Study for the effectivity of low-dose radon hyperthermia therapy in the Gastein healing gallery on atopic dermatitis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN40955970

Enrollment

Registered

2021-06-29

Start date

2017-01-25

Completion date

Unknown

Last updated

2024-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Effectivity of low-dose radon hyperthermia therapy on atopic dermatitis Skin and Connective Tissue Diseases Atopic dermatitis

Interventions

Patients with Atopic Dermatitis (AD) are recruited via the department of dermatology of the Salzburger Landeskliniken (Prim. Dr. Johann Bauer, SALK). Patients are randomised to control (sauna treatme

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Atopic Dermatitis, from chronic moderate to severe disease state. (mild: SCORAD 50) 2. Patient SCORAD value must be between 25 and 50 for inclusion 3. AD must be diagnosed and verified by a dermatologist 4. Age range 18 - 70 years 5. Signed Informed Consent must be obtained from each patient 6. Patients must be able to fill out a questionnaire by themselves

Exclusion criteria

Exclusion criteria: 1. Pregnancy or breast feeding period 2. Incompatibility of patients to treatment methods 3. Erosions, ulcers 4. Viral or bacterial superinfections 5. Severe internal diseases 6. Consumption of potential photosensitizers 7. Concomitant or past malignant skin tumors 8. Radon therapy or similar radiation (UV/light) treatment within the past year 9. Consumption of oral immunosuppressive drugs (within 6 months before entering the study) 10. Claustrophobia

Design outcomes

Primary

Measure	Time frame
SCORAD (SCORing Atopic Dermatitis) questionnaire for specific assessment of skin condition in AD at before, directly after cure stay and 3, 6, and 9 months after the end of the cure stay.	—

Secondary

Measure	Time frame
Measured before, directly after cure stay, and three, six, and nine months after the end of the cure stay: 1. Quality of life (EQ-5D-5L) 2. Skin condition (SKINDEX-29) 3. Analysis of blood samples (MDC/CCL22, CTACK/CCL27, TARC/CCL17, IgE, IL-4, IL-13)	—

Countries

Austria, Germany

Contacts

Public ContactJulia Fuchs

julia.fuchs@pmu.ac.at+43 662 2420-80511

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026